This New CEO Hits the Ground Running
Today, Fool.com healthcare bureau chief Brenton Flynn looks at AstraZeneca's brand-new CEO's announcement that the company is suspending share repurchases effective immediately. Given that AstraZeneca is facing a major patent cliff on the horizon, this is likely a wise decision. It will need to keep that powder dry in the event that they have to perform an acquisition.
There have been whispers that Forest Laboratories is the most likely target. While the two certainly have synergies, there are risks as well, particularly differences across the companies' R&D structure.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
The article This New CEO Hits the Ground Running originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.